Huntington National Bank cut its stake in Eli Lilly and Company (NYSE:LLY) by 4.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 182,395 shares of the company’s stock after selling 7,657 shares during the period. Huntington National Bank’s holdings in Eli Lilly and were worth $15,011,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. BlackRock Inc. increased its stake in shares of Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after buying an additional 59,978,664 shares in the last quarter. Beutel Goodman & Co Ltd. acquired a new stake in shares of Eli Lilly and during the first quarter valued at $161,084,000. Vanguard Group Inc. increased its stake in shares of Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock valued at $5,769,694,000 after buying an additional 2,181,701 shares in the last quarter. Winslow Capital Management LLC increased its stake in shares of Eli Lilly and by 79.7% in the first quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock valued at $326,008,000 after buying an additional 1,719,538 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Eli Lilly and by 93.6% in the first quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock valued at $250,681,000 after buying an additional 1,441,200 shares in the last quarter. 75.59% of the stock is owned by institutional investors and hedge funds.
Eli Lilly and Company (NYSE:LLY) traded up 0.75% during mid-day trading on Tuesday, hitting $82.10. The stock had a trading volume of 647,023 shares. The stock has a 50-day moving average price of $82.84 and a 200 day moving average price of $81.87. The firm has a market cap of $86.62 billion, a P/E ratio of 35.53 and a beta of 0.34. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $86.72.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period last year, the firm earned $0.86 EPS. Equities analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be issued a $0.52 dividend. The ex-dividend date is Friday, August 11th. This represents a $2.08 annualized dividend and a dividend yield of 2.55%. Eli Lilly and’s dividend payout ratio is currently 90.04%.
WARNING: This article was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://stocknewstimes.com/2017/08/15/eli-lilly-and-company-lly-stake-reduced-by-huntington-national-bank.html.
LLY has been the subject of several recent analyst reports. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $92.00 price target on shares of Eli Lilly and in a report on Tuesday, May 16th. BMO Capital Markets set a $71.00 target price on Eli Lilly and and gave the stock a “sell” rating in a report on Tuesday, April 25th. Zacks Investment Research downgraded Eli Lilly and from a “buy” rating to a “hold” rating in a report on Tuesday, April 18th. Credit Suisse Group reaffirmed an “outperform” rating and set a $87.00 target price on shares of Eli Lilly and in a report on Wednesday, April 19th. Finally, Argus downgraded Eli Lilly and from a “buy” rating to a “hold” rating and lifted their target price for the stock from $64.18 to $81.00 in a report on Thursday, April 27th. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $88.27.
In other news, VP Michael J. Harrington sold 22,833 shares of the firm’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $79.97, for a total value of $1,825,955.01. Following the completion of the sale, the vice president now directly owns 62,056 shares of the company’s stock, valued at approximately $4,962,618.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Melissa S. Barnes sold 1,900 shares of the firm’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $80.78, for a total value of $153,482.00. Following the completion of the sale, the insider now directly owns 14,041 shares of the company’s stock, valued at $1,134,231.98. The disclosure for this sale can be found here. Insiders sold a total of 669,733 shares of company stock valued at $55,845,287 over the last three months. Insiders own 0.20% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
